Angiotensin-converting enzyme inhibitors, left ventricular dysfunction, and early heart failure

Area of Science:

• Cardiology
• Pharmacology
• Exercise Physiology

Background:

• Left ventricular systolic dysfunction (LVSD) significantly impacts exercise capacity.
• Angiotensin-converting enzyme (ACE) inhibitors are standard treatments for heart failure.
• The specific effects of ACE inhibitors like lisinopril on exercise performance in LVSD patients require further elucidation.

Purpose of the Study:

• To investigate the impact of the ACE inhibitor lisinopril on exercise performance in patients with major impairment of left ventricular systolic function.
• To assess the hemodynamic and hormonal effects of lisinopril in this patient population.

Main Methods:

• A randomized, double-blind, crossover study involving 18 patients with LVSD.
• Patients received either lisinopril (2.5-10 mg daily) or placebo for 6 weeks.
• Exercise performance was evaluated using low- and high-intensity protocols, alongside hemodynamic and hormonal measurements.

Main Results:

• Lisinopril did not significantly alter resting blood pressure or heart rate.
• No effect on exercise duration was observed during low-intensity exercise.
• A trend toward improved exercise time and a significant increase in peak oxygen consumption were noted during high-intensity exercise.
• Lisinopril increased renal blood flow, decreased glomerular filtration rate, and altered plasma hormone levels (decreased angiotensin II, aldosterone, atrial natriuretic peptide; increased active renin).

Conclusions:

• Lisinopril may offer benefits for exercise capacity, particularly peak oxygen consumption, in patients with LVSD during high-intensity activities.
• The drug modulates the renin-angiotensin-aldosterone system and impacts renal hemodynamics.
• Further research is warranted to confirm these findings and explore clinical implications.